Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New class of antidiabetic drugs for type 2 diabetes shows promise

Staff Writer
Staff Writer 1 month ago
Updated 2022/07/14 at 5:01 AM
Share
SHARE

As part of research in Diabetes, a collaborative team of experts from academic institutions in the UK and Australia reportedly developed a new class of antidiabetic drugs referred to as PATAS.

The mechanism of action involves the targeting of adipocytes, restoration of glucose entry, and re-establishment of the metabolic physiology of the adipose tissue.

The study was conducted on animal subjects; researchers have their sights set on clinical trials in the near future.

What the study determined: ” ALMS1 was found to bind to protein kinase C-α (PKCα) in the adipocyte, and upon insulin signaling, PKCα is released from ALMS1. α-Helices in the kinase domain of PKCα were therefore screened to identify a peptide sequence that interfered with the ALMS1-PKCα protein interaction. When incubated with cultured human adipocytes, the stapled peptide termed PATAS, for Peptide derived of PKC Alpha Targeting AlmS, triggered insulin-independent glucose absorption, de novo lipogenesis, and cellular glucose utilization.”

“In vivo, PATAS reduced whole-body insulin resistance, and improved glucose intolerance, fasting glucose, liver steatosis, and fibrosis in rodents. Thus, PATAS represents a novel first-in-class peptide that targets the adipocyte to ameliorate insulin resistance and its associated comorbidities.”

You Might Also Like

Pregnant women with epilepsy may be at more risk of depression and anxiety symptoms

Researchers find high cholesterol may not raise the risk of dementia

Study unveils the leisure activities that may lower the risk of dementia

MIT study shows how microglia can contribute to Alzheimer’s disease

New paper refutes theory that the human brain shrank 3,000 years ago

TAGGED: PATAS, type 2 diabetes
Staff Writer July 13, 2022
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Researchers uncover a new gene implicated in neurodevelopmental delays
Next Article Study finds high rates of incarceration may not yield community safety

Recommended

Clinical

Pregnant women with epilepsy may be at more risk of depression and anxiety symptoms

1 Min Read
Clinical

Researchers find high cholesterol may not raise the risk of dementia

1 Min Read
Clinical

Study unveils the leisure activities that may lower the risk of dementia

1 Min Read
Clinical

MIT study shows how microglia can contribute to Alzheimer’s disease

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?